PL3145508T3 - Nanocząstki klewidypiny i ich kompozycje farmaceutyczne - Google Patents

Nanocząstki klewidypiny i ich kompozycje farmaceutyczne

Info

Publication number
PL3145508T3
PL3145508T3 PL15795707.7T PL15795707T PL3145508T3 PL 3145508 T3 PL3145508 T3 PL 3145508T3 PL 15795707 T PL15795707 T PL 15795707T PL 3145508 T3 PL3145508 T3 PL 3145508T3
Authority
PL
Poland
Prior art keywords
clevidipine
nanoparticles
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL15795707.7T
Other languages
English (en)
Inventor
Rajeshwar Motheram
Sr. David C. HANLEY
Akif Emre TÜRELI
Monika KANTER
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3145508T3 publication Critical patent/PL3145508T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
PL15795707.7T 2014-05-19 2015-05-19 Nanocząstki klewidypiny i ich kompozycje farmaceutyczne PL3145508T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462000119P 2014-05-19 2014-05-19
PCT/US2015/031470 WO2015179334A1 (en) 2014-05-19 2015-05-19 Clevidipine nanoparticles and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PL3145508T3 true PL3145508T3 (pl) 2023-10-23

Family

ID=54554604

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15795707.7T PL3145508T3 (pl) 2014-05-19 2015-05-19 Nanocząstki klewidypiny i ich kompozycje farmaceutyczne

Country Status (10)

Country Link
US (2) US11737989B2 (pl)
EP (1) EP3145508B1 (pl)
KR (1) KR102380701B1 (pl)
CN (2) CN106456617A (pl)
CA (1) CA2947486C (pl)
ES (1) ES2950154T3 (pl)
MX (1) MX2016015208A (pl)
PL (1) PL3145508T3 (pl)
RU (1) RU2759673C2 (pl)
WO (1) WO2015179334A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105796494B (zh) * 2016-04-01 2019-10-11 广东药科大学 一种含氨基酸的尼莫地平亚微乳注射液及其制备方法
CN105796490B (zh) * 2016-04-01 2019-12-10 广东药科大学 一种含氨基酸的尼莫地平注射液组合物及其制备方法
CN107281104B (zh) * 2017-05-27 2021-02-02 济南康和医药科技有限公司 一种丁酸氯维地平磷脂复合物脂质体及其制备方法
EP3804703A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung eines nanopartikulären wirkstoffs
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453523A (en) * 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
AU2007247770B2 (en) * 2006-05-04 2013-07-18 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
PL2320740T3 (pl) 2008-08-01 2014-09-30 The Medicines Co Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń
US8679344B2 (en) * 2008-12-17 2014-03-25 Cerion Technology, Inc. Process for solvent shifting a nanoparticle dispersion
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US8852644B2 (en) * 2010-03-22 2014-10-07 Instillo Gmbh Method and device for producing microparticles or nanoparticles
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
HUE026295T2 (en) * 2010-10-12 2016-06-28 The Medicines Co Clevidipine emulsion formulations containing antimicrobial agents
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
EP2526926A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
AU2012303683B2 (en) * 2011-08-26 2016-09-08 Wockhardt Limited Methods for treating cardiovascular disorders
US20150246137A1 (en) * 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
EA030354B1 (ru) 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
CN103479577A (zh) * 2013-09-30 2014-01-01 山东大学 含有丁酸氯维地平的脂质纳米混悬剂及其冻干制剂

Also Published As

Publication number Publication date
EP3145508A4 (en) 2018-01-24
KR102380701B1 (ko) 2022-03-31
WO2015179334A1 (en) 2015-11-26
US20170087093A1 (en) 2017-03-30
EP3145508A1 (en) 2017-03-29
RU2759673C2 (ru) 2021-11-16
RU2016149538A (ru) 2018-06-20
CN114668740A (zh) 2022-06-28
KR20170032886A (ko) 2017-03-23
CA2947486C (en) 2023-09-26
BR112016027104A2 (pt) 2018-07-10
US20230145206A1 (en) 2023-05-11
US11737989B2 (en) 2023-08-29
EP3145508C0 (en) 2023-07-05
ES2950154T3 (es) 2023-10-05
EP3145508B1 (en) 2023-07-05
RU2016149538A3 (pl) 2019-01-17
MX2016015208A (es) 2017-03-23
CA2947486A1 (en) 2015-11-26
CN106456617A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
HK1258900A1 (zh) 遞送方法和組合物
HK1259145A1 (zh) 3-脫氧衍生物及其藥物組合物
HK1251153A1 (zh) 一種藥物組合物及其應用
IL252967A0 (en) Pharmaceutical preparations containing plasminogen and their uses
HK1252026A1 (zh) 藥物組合及其應用
HK1254054A1 (zh) 富馬酸二甲酯顆粒和其藥物組合物
HK1245086A1 (zh) 處方藥物組成及其製備和使用
PT3223796T (pt) Composições farmacêuticas, preparação e suas utilizações
ZA201703398B (en) Pharmaceutical composition and methods
HK1245085A1 (zh) 處方藥物組成及其製備和使用
EP3145508C0 (en) CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF
HK1245113A1 (zh) 藥物組合物及其用途
HK1232211A1 (zh) 二甲基吡啶胺衍生物及其醫藥用途
GB201406172D0 (en) Therapy and pharmaceutical composition
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
GB201700560D0 (en) Pharmaceutical composition comprising docetaxel
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
IL253174B (en) Nano-particles and methods for their preparation
GB201520755D0 (en) Nanoparticle formulations and their uses
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses
EP3400233A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS
GB201521306D0 (en) Compositions comprising nanoparticles and methods thereof
GB201419354D0 (en) Pharmaceutical extracts and uses thereof